Vehicle proprietary ophthalmic solution for presbyopia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 24 Mar 2022: Trial registered, NCT05294328
  2. 5 May 2022: Trial started, NCT05294328
  3. 24 Jun 2022: Trial registered, NCT05431543
  4. 6 Aug 2022: Trial started, NCT05431543

The trials

NCT05294328: Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

State
Completed
Phase
Phase 2
People
68 taking part
Started
5 May 2022
Primary completion
22 Aug 2022
Arms
Vehicle Ophthalmic Solution dosed bilaterally
Results
Posted on the registry
  1. 24 Mar 2022: Trial registered
  2. 5 May 2022: Trial started
  3. 10 Sep 2022: Trial completed
  4. 5 Sep 2024: Trial results posted

NCT05431543: Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

State
Completed
Phase
Phase 2
People
59 taking part
Started
6 Aug 2022
Primary completion
14 Dec 2022
Arms
Vehicle Ophthalmic Solution dosed bilaterally
Results
Posted on the registry
  1. 24 Jun 2022: Trial registered
  2. 6 Aug 2022: Trial started
  3. 14 Dec 2022: Trial completed
  4. 5 Sep 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.